Ensysce Payout Ratio vs Operating Cash Flow Per Share Analysis
| ENSC Stock | USD 0.49 0.01 2.00% |
Ensysce Biosciences financial indicator trend analysis is much more than just examining Ensysce Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ensysce Biosciences is a good investment. Please check the relationship between Ensysce Biosciences Payout Ratio and its Operating Cash Flow Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
Payout Ratio vs Operating Cash Flow Per Share
Payout Ratio vs Operating Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ensysce Biosciences Payout Ratio account and Operating Cash Flow Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Ensysce Biosciences' Payout Ratio and Operating Cash Flow Per Share is -0.29. Overlapping area represents the amount of variation of Payout Ratio that can explain the historical movement of Operating Cash Flow Per Share in the same time period over historical financial statements of Ensysce Biosciences, assuming nothing else is changed. The correlation between historical values of Ensysce Biosciences' Payout Ratio and Operating Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payout Ratio of Ensysce Biosciences are associated (or correlated) with its Operating Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Cash Flow Per Share has no effect on the direction of Payout Ratio i.e., Ensysce Biosciences' Payout Ratio and Operating Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | -0.29 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Payout Ratio
Payout Ratio is the proportion of Ensysce Biosciences earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Ensysce Biosciences dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Ensysce Biosciences is paying out more in dividends than it makes in net income.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Most indicators from Ensysce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ensysce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.At present, Ensysce Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.22, whereas Issuance Of Capital Stock is forecasted to decline to about 8.5 M.
| 2023 | 2024 (projected) | Interest Income | 98.6K | 93.6K | Tax Provision | 281.2K | 373.2K |
Ensysce Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Ensysce Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ensysce Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 196.5M | 351.8K | 16.4M | 5.9M | 2.7M | 2.6M | |
| Total Current Liabilities | 2.8M | 7.0M | 16.5M | 9.5M | 3.3M | 6.2M | |
| Total Stockholder Equity | 186.2M | (6.4M) | (8.2M) | (4.0M) | (322.9K) | (306.7K) | |
| Retained Earnings | 2.5M | (56.0M) | (85.8M) | (110.9M) | (121.6M) | (115.5M) | |
| Cash | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M | |
| Other Assets | 5K | 3.8K | 754.8K | 585.9K | 527.3K | 500.9K | |
| Cash And Short Term Investments | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M | |
| Common Stock Shares Outstanding | 98.3K | 68.8K | 84.0K | 179.9K | 2.3M | 3.9M | |
| Long Term Debt Total | 566.3K | 791.3K | 4.4M | 140.2K | 161.2K | 153.1K | |
| Liabilities And Stockholders Equity | 196.5M | 351.8K | 16.4M | 5.9M | 2.7M | 2.6M | |
| Capital Surpluse | 2.9M | 2.5M | 78.0M | 107.2M | 123.3M | 129.5M | |
| Total Liab | 10.3M | 7.0M | 24.6M | 9.9M | 3.4M | 3.2M | |
| Total Current Assets | 1.2M | 347.9K | 15.7M | 5.3M | 2.3M | 2.2M | |
| Short Term Debt | 2.6M | 4.3M | 12.7M | 4.3M | 854.7K | 812.0K | |
| Common Stock | 181.2M | 1.6K | 2.5K | 642.0 | 315.0 | 299.25 | |
| Other Current Liab | 2.8M | 856.0K | 3.4M | 2.3M | 542.3K | 515.1K | |
| Net Debt | (494.9K) | 4.1M | 483.4K | 1.3M | (268.9K) | (255.5K) | |
| Accounts Payable | 540.8K | 1.7M | 301.1K | 2.9M | 1.9M | 1.4M | |
| Non Current Assets Total | 195.3M | 3.9K | 754.8K | 585.9K | 419.2K | 398.3K | |
| Non Currrent Assets Other | (351.0) | 3.8K | (24.7B) | 558.7K | 419.2K | 440.2K | |
| Non Current Liabilities Total | 7.6M | 6.8M | 8.1M | 450.5K | 26.4K | 25.1K | |
| Other Current Assets | 138.6K | 153.7K | 3.4M | 2.2M | 1.1M | 1.3M | |
| Other Stockholder Equity | 2.5M | 49.5M | 77.7M | 106.9M | 121.2M | 127.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.